Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma

* Early results showed 2 laBCC (locally advanced Basal Cell Carcinoma) subjects out of 10 experienced a Partial Response (30% decrease in tumor size) at week #24. * The first biopsy analysis in the laBCC subject showed a more than 90% decrease of GLI-1 expression at week #8 (GLl-1 is involved...

2022-03-28 19:00 2571

Hyperflex® Balloon Catheter by Endovastec™ Receives Marketing Approval in Japan

SHANGHAI, March 28, 2022 /PRNewswire/ -- Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently announced that it has received registration approval from Japan Pharmaceuticals and Medical Devices Agency (PMDA) for its independently-developed Hyperflex® Balloon Catheter (...

2022-03-28 12:29 3224

InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China

BEIJING, March 27, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) announced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its TYK2 JH2 allosteric inhibitor ICP-488, which is the Compan...

2022-03-28 10:48 2413

Innovent and Lilly Expand Strategic Partnership in Oncology

SAN FRANCISCO and INDIANAPOLIS and SUZHOU, China, March 28, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and...

2022-03-28 08:00 7509

Ascletis Announces the Latest Results of the Preclinical Studies of Two Novel Anti-Cancer Drug Candidates, ASC61 and ASC60, to be presented at AACR Annual Meeting 2022

HANGZHOU, China and SHAOXING, China, March 27, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) today announces that the latest preclinical research results of the company's two novel anti-cancer drug candidates, ASC61, an oral PD-L1 inhibitor and ASC60, an oral fatty acid synthase (FASN) i...

2022-03-27 18:30 5097

Kintor Pharma Announces 2021 Business Progress and Annual Results

SUZHOU, China, March 25, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year endedDecember 3...

2022-03-26 01:23 8618

Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG

SHANGHAI, March 25, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that its first self-developed innovative PD-1 inhibitor HANSIZHUANG (generic name: serplulimab injection) has been approved by the National Medical Products Administration (NMPA)for the treatment of adult ...

2022-03-25 21:24 6862

Abcam the most awarded company at 2022 industry awards

CAMBRIDGE, England, March 25, 2022 /PRNewswire/ -- Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions fromCiteAb at their annual industry awards , the highest of any participant evaluated this...

2022-03-25 20:40 5712

Modern Chinese Medicine Announces Year 2021 Annual Results

Solid growth driven by extensive distribution network and strong R&D PERFORMANCE HIGHLIGHTS * The Group posted a consolidated revenue of approximately RMB360.7 million for the year ended31 December 2021, representing an increase of approximately 16.8% * For the year ended 31 December 2021, t...

2022-03-25 10:39 4892

Harbour BioMed Reports Full Year 2021 Financial Results: Empower Value Creation with Global Innovation Capabilities

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, March 24, 2022 /PRNewswire/ --Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology a...

2022-03-25 10:22 3907

New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer

SYDNEY, March 24, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that an investigator-initiated trial (IIT) will commence shortly...

2022-03-24 21:08 2678

Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets

The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices NEW YORK, Ma...

2022-03-24 21:00 4906

Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets

Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care

Huma acquires AstraZeneca's digital health platform AMAZE™ and AstraZeneca becomes a shareholder of Huma LONDON and NEW YORK, March 23, 2022 /PRNewswire/ -- Huma Therapeutics Limited , a global digital health technology company advancing digital-first care delivery and res...

2022-03-24 07:00 4330

Fosun International Announces 2021 Annual Results: Total Revenue Increased by 18% to RMB161.29 Billion, Striving to Pursue Steady and Sustainable Development

2021 Annual Results Summary and Highlights: * Total operating revenue for the year amounted to RMB161.29 billion, representing a year-on-year increase of 18%; profit attributable to owners of the parent reachedRMB10.09 billion, representing a year-on-year increase of 26%; * Profit of industria...

2022-03-23 23:01 4963

Telix Advances Development of Glioblastoma Therapy Program

MELBOURNE, Australia, March 23, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has made significant progress in advancing the Company's glioblastoma multiforme (GBM) therapy candidate TLX101 into the next stage of clinical development. TLX101 (4-L-...

2022-03-23 10:16 2858

Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India

* First authorization of Novavax' COVID-19 vaccine in adolescent population received * Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorizedfor adolescents ≥12 to <18 inIndia * Authorization highligh...

2022-03-23 09:31 4671

InnoCare Releases 2021 Annual Results and Business Highlights

BEIJING, March 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 annual results as of31 December 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "We are delighted ...

2022-03-23 08:08 4063

Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results

– Advancing key programs in HBV, CNS, and HIV – – Received first BLA approval for COVID-19 Treatment in China and added to China's latest COVID-19 Diagnosis and Treatment Guidelines– – Multiple clinical value drivers expected across the portfolio in 2022 and beyond – – Cash, bank balances, an...

2022-03-23 07:20 6092

Fosun Pharma 2021 Annual Results Announcement: Accelerating the Globalization Comprehensively

The Proportion of Revenue from Innovative Products Continues to Increase Highlights: * Revenue for the year ended December 31, 2021 was RMB39,005 million, representing an increase of 28.70% YOY; * The proportion of revenue from new products as well as regions outside Mainland China and count...

2022-03-23 06:53 4196

WuXi Biologics Achieved Record Growth and Profitability in 2021

Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million Net Profit Grew by 107.3% Y-o-Y to RMB3,508.6 Million Adjusted Net Profit Rose by 100.3% to RMB3,435.9 Million Total Backlog Grew 20.1% to ...

2022-03-23 00:38 3920

1 ... 313 314 315316317 318 319 ... 349